4					
1	Title: Monocytes and macrophages, targets of SARS-CoV-2:				
2	the clue for Covid-19 immunoparalysis				
3					
4	Running title: Covid-19 immunoparalysis of myeloid cells				
5					
6	Asma Boumaza ^{1,2*} , Laetitia Gay ^{1,2*} , Soraya Mezouar ^{1,2*} , Aïssatou Bailo Diallo ^{1,2} ,				
7	Moise Michel ^{1,2} , Benoit Desnues ^{1,2} , Didier Raoult ^{1,2} , Bernard La Scola ^{1,2} , Philippe Halfon ^{1,2} ,				
8	Joana Vitte ^{1,2} , Daniel Olive ³ and Jean-Louis Mege ^{1,2,4#}				
9	Air Marseille Hairs IDD, AD HM, MEDILL Marseille, Erstere				
10	¹ Aix-Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France				
11	² IHU-Méditerranée Infection, Marseille, France				
12	³ CRCM, Inserm UMR1068, CNRS UMR7258, Institut Paoli Calmettes, Marseille, France				
13	⁴ Aix-Marseille Univ, APHM, Hôpital de la Conception, Laboratoire d'Immunologie,				
14	Marseille, France				
15 16	*Contributed equally				
10	Contributed equality				
17	<u>[#]Corresponding author :</u>				
19	Professor Jean-Louis MEGE				
20	IHU Méditerranée Infection				
20 21	19-21, Boulevard Jean Moulin				
22	13385 Marseille, France				
23	Phone: (+33) 4 13 73 20 51				
24	Fax: (+33) 4 13 73 20 52				
25	E-mail: jean-louis.mege@univ-amu.fr				
26					
27	Text word count : 3936				
27	Text word count : 3930				
28	Abstract word count : 211				
29	Number of figures: 5				
30	Number of supplemental figures: 3				
31	Number of tables: 2				
51					

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.17.300996. this version posted September 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

32 Number of references: 43

33 Abstract

34 To date, the Covid-19 pandemic affected more than 18 million individuals and caused more 35 than 690, 000 deaths. Its clinical expression is pleiomorphic and severity is related to age and 36 comorbidities such as diabetes and hypertension. The pathophysiology of the disease relies on 37 aberrant activation of immune system and lymphopenia that has been recognized as a 38 prognosis marker. We wondered if the myeloid compartment was affected in Covid-19 and if 39 monocytes and macrophages could be infected by SARS-CoV-2. We show here that SARS-40 CoV-2 efficiently infects monocytes and macrophages without any cytopathic effect. 41 Infection was associated with the secretion of immunoregulatory cytokines (IL-6, IL-10, 42 TGF- β) and the induction of a macrophagic specific transcriptional program characterized by 43 the upregulation of M2-type molecules. In addition, we found that in vitro macrophage 44 polarization did not account for the permissivity to SARS-CoV-2, since M1- and M2-type 45 macrophages were similarly infected. Finally, in a cohort of 76 Covid-19 patients ranging 46 from mild to severe clinical expression, all circulating monocyte subsets were decreased, 47 likely related to massive emigration into tissues. Monocytes from Covid-19 patients exhibited 48 decreased expression of HLA-DR and increased expression of CD163, irrespective of the 49 clinical status. Hence, SARS-CoV-2 drives circulating monocytes and macrophages inducing 50 immunoparalysis of the host for the benefit of Covid-19 disease progression.

51

52 Keywords: SARS-CoV-2, Covid-19, monocytes, macrophages, polarization

53 Introduction

54 The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/2019-n-55 CoV) emerged in Wuhan (China) at the end of 2019 and caused the coronavirus disease of 56 2019 (Covid-19) pandemic in a few weeks, affecting more than 18 million people and killing 57 more than 690,000 to date (1). The disease is characterized by a strikingly heterogeneous 58 clinical presentation and prognosis. Most patients are pauci-symptomatic or have fever, cough 59 and fatigue, while a minority experience progression to an acute respiratory distress syndrome 60 or other critically severe conditions. The severity of the disease is related to underlying 61 conditions such as hypertension, diabetes, coronary heart diseases or obesity (2). The 62 mechanisms of the disease remain elusive at this stage, but evidence for a prominent role of 63 the immune system is accumulating. The severity of Covid-19 pneumonia is associated with 64 lymphopenia and a cytokine release syndrome (CRS) (3), which contributes to the massive 65 migration of T cells into tissues, mainly the lung as revealed by accumulation of T cells 66 within lesions (4).

67 There is evidence that myeloid cells may be involved in the pathophysiology of 68 coronavirus infection, either directly, as a targets for the virus, or indirectly, as effectors of the 69 CRS (5). Indeed, it is known from previous coronavirus outbreaks that macrophages are 70 susceptible to MERS-CoV and SARS-CoV-1 infection (6). Recently, macrophage and 71 monocyte accumulation in the alveolar lumen has been shown in a humanized mice model of 72 SARS-CoV-2 expressing human angiotensin-converting enzyme 2 (ACE2) (7). In addition, 73 SARS-CoV-2 nucleocapsid protein has been detected in lymph nodes and spleen-associated 74 $CD169^+$ macrophages from Covid-19 patients (8). Finally, single cell RNA sequencing of 75 pulmonary tissue from Covid-19 patients revealed an expansion of interstitial macrophages 76 and monocyte-derived macrophages (MDM) but not of alveolar macrophages (9). However, 77 whether circulating monocytes and/or macrophages are targets of SARS-CoV-2 and whether 78 monocyte diversity is altered in Covid-19 patients require specific investigation since most 79 studies are based on this hypothesis.

Monocytes are innate hematopoietic cells that maintain vascular homeostasis and ensure early responses to pathogens during acute infections. Three distinct human monocyte subsets are described, based on the expression of CD14 and CD16 surface antigens: classical CD14⁺CD16⁻ monocytes, intermediate CD14⁺CD16⁺ monocytes, and non-classical CD14⁻ CD16⁺ monocytes (10,11). Recently, it has been shown in murine models that classical monocytes are the precursors of non-classical monocytes (12). There is evidence that 86 monocyte subsets exhibit a certain degree of functional specialization. During bacterial 87 infection, classical monocytes are recruited to the sites of inflammation, where they exert 88 typical phagocytic functions and can differentiate into inflammatory dendritic cells or 89 macrophages. Non-classical monocytes crawl along vasculature and surveil the vascular tissue 90 (13). Alterations of monocyte subset frequency have been reported in infectious and 91 inflammatory diseases (10). While macrophages largely arise from monocytes in acute 92 situations such as infection, under homeostatic conditions most tissue macrophages are of 93 embryonic origin and monocytes merely renew this population (14). Consequently, the 94 mobilization of immune cells in Covid-19 might lead to macrophage populations of multiple 95 origin in tissue lesions.

96 We show here that SARS-CoV-2 has the ability to infect human monocytes and 97 macrophages. SARS-CoV-2 infection stimulated the production of immunoregulatory 98 cytokines, interleukin (IL)-6 and IL-10 in both cell types and triggered in macrophages an 99 original transcriptional program enriched with M2-type genes. Macrophage polarization did 100 not account for permissivity to the virus since M1- and M2-polarized cells were similarly 101 infected by SARS-CoV-2. In Covid-19 patients, the numbers of classical, intermediate and 102 non-classical monocytes were decreased, irrespective of the level of severity. Their expression 103 of CD163, a molecule associated with the immunoregulatory phenotype, was significantly 104 higher than in healthy controls, whereas that of HLA-DR was decreased. Hence, SARS-CoV-105 2 drives circulating monocytes and macrophages, inducing immunoparalysis of the host for 106 the benefit of Covid-19 disease progression.

107 **Results**

108 SARS-CoV-2 infects monocytes and macrophages and stimulates cytokine release

109 It has been shown that monocytes and macrophages express receptors for SARS-CoV-2 (24), 110 suggesting that the virus targets myeloid cells. We wondered whether SARS-CoV-2 was able 111 to infect human monocytes and macrophages. Monocytes, MDM and Vero cells were 112 incubated with SARS-CoV-2 strain IHU-MI3 (0.1 MOI) for 24 and 48 hours and infection 113 level was measured by RT-PCR and immunofluorescence. SARS-CoV-2 infected efficiently 114 Vero cells (Ct=18.69) after 24 hours, but a lytic process prevented the measurement of viral 115 replication, (Figure 1A). Monocytes were also infected after 24 hours (Ct=22.44), but the 116 viral load remained constant thereafter (Ct=22.2) (Figure 1A). Similarly, macrophages were 117 efficiently infected with the SARS-CoV-2 strain IHU-MI3 after 24 (Ct=22.49) and 48 hours 118 (Ct=19.67). In contrast to Vero cells, monocytes and macrophages were not uniformly 119 infected, as observed by confocal microscopy (Figure 1A, right panel). We next addressed 120 the ability of the IHU-MI3 strain of SARS-CoV-2 to induce the release of soluble mediators 121 from monocytes and MDMs. IL-1 β , IL-6, IL-10, TNF- α , IFN- β and TGF- β 1 levels were 122 measured in supernatants of monocytes or MDM stimulated with SARS-CoV-2 for 24 and 48 123 hours. IL-6, IL-10, and IL-1 β levels were significantly increased in stimulated monocyte 124 supernatants as compared to unstimulated conditions after 24 hours (Figure 1B) and were 125 persistently increased after 48 hours (Figure 1C), whereas no difference was observed for 126 TNF-α. In MDM supernatants, levels of IL-6 and IL-10 were increased after 24 and 48 hours 127 (Figure 1B and C). TGF- β levels were significantly increased in supernatants from 128 monocytes and MDMs after 48 hours of stimulation. IFN- β was never detected in 129 supernatants from monocytes or macrophages stimulated by SARS-CoV-2 (Figure 1B and 130 C). Taken together, SARS-CoV-2 infects monocytes and macrophages. The virus stimulates 131 the release of both pro- and anti-inflammatory cytokines.

132

133 SARS-CoV-2 elicits a specific transcriptional program in macrophages

Next, the expression of genes involved in the inflammatory response (*IFNA*, *IFNB*, *IFNG*, *TNF*, *IL1B*, *IL6*, *IL8*, *CXCL10*) or immunoregulation, (*IL10*, *TGFB1*, *CD163*) was measured by qRT-PCR in monocytes and MDM incubated with the virus for 24 and 48 hours. PCA of gene expression using ClustVis software showed that unstimulated and SARS-CoV-2stimulated monocytes exhibited superimposable programs; in contrast, unstimulated and SARS-CoV-2-stimulated transcriptional programs were clearly distinct in macrophages 140 (Figure 2A). In monocytes, a 24 hour-incubation with SARS-CoV-2 stimulated the

141 expression of the whole gene panel, but only *IFNA* gene variation reached the significance

142 level (**Figure 2B**). After 48 hours, expression of *IFNA* declined to levels of unstimulated cells

143 and there was no other change in gene expression (Suppl figure 1), suggesting that SARS-

144 CoV-2 was only able to activate gene expression in monocytes in a transient manner.

- 145 We next investigated the transcriptional program induced by SARS-CoV-2 in macrophages.
- 146 Similar to monocytes, at 24 hours, SARS-CoV-2 significantly increased the expression of
- 147 antiviral (IFNA and IFNB), inflammatory (CXCL10 and TNF), and immunoregulatory genes
- 148 (*TGFB1* and *CD163*) (Figure 2B). The increase in gene expression was no longer observed
- 149 after 48 hours except for *TGFB* and *CD163* (**Suppl figure 1**). Hence, the early transcriptional
- 150 program of infected macrophages consisted of genes associated with M1 profile (type I IFN,
- 151 *CXCL10*) and M2 profile (*TGFB1* and *CD163*), suggesting that SARS-CoV-2 does not induce
- 152 clear polarization of macrophages at the onset of the infection but rather a delayed shift153 toward a M2-type.
- 154

155 Macrophage polarization and SARS-CoV-2 infection

156 As SARS-CoV-2 induced an early M1/M2 followed by a late M2 program in macrophages, 157 we investigated the effect of macrophage polarization status on infection. MDM polarization 158 was induced by IFN- γ (20 ng/ml) and lipopolysaccharide (100 ng/ml) (M1), IL-4 (20 159 ng/ml) (M2), or was kept at a resting state without polarization (M0). The polarization status 160 was confirmed by measuring the expression of M1 (IL1B, IL1RA, IL6, IL12, CXCL10, TNF, 161 NOS2, IFNG) and M2 genes (ARG1, IL10, MR, CD163, TGFB). PCA and hierarchical 162 clustering confirmed the induction of three distinct activation statuses (**Suppl. figure 2**). The 163 expression of polarization-related genes was investigated after 24 and 48 hours of SARS-164 CoV-2 stimulation of M1 and M2 polarized macrophages. The hierarchical clustering showed 165 that unstimulated and SARS-CoV-2-stimulated MDM (M0, M1 and M2) were present on two 166 distinct branches but the discrimination of responses as a function of polarization was not 167 possible (Suppl figure 3). Regarding pro- (IL-6, TNF) and anti- (IL-10, TGF-B) 168 inflammatory cytokines, SARS-CoV-2 stimulation significantly increased the release of both 169 cytokine groups in M1- and M2-polarized macrophages after 24 and 48 hours (Figure 3A, B). 170 In addition, no differences were observed in the viral load of M0, M1 or M2 macrophages 171 (Figure 3C). We next performed the same experiment using M0, M1 or M2 THP-1 172 macrophages. The choice of a cell line instead of primary macrophages aimed at minimizing

173 inter-individual variations. When THP-1 macrophages were M1 polarized, the viral load was

174 similar to that of non-polarized (M0) macrophages. In contrast, SARS-CoV-2 load was

significantly decreased in M2 polarized macrophages as compared with M0 macrophages

176 (Figure 3C). Although a type 2 immune response was associated with lesser infection of

- 177 macrophages, their polarization did not appear critical for SARS-CoV-2 infection.
- 178

179 Monocyte subsets are altered in SARS-CoV-2-infected patients

180 Following the demonstration of a direct in vitro effect of SARS-CoV-2 on monocytes and 181 macrophages, we wondered if the frequency of monocyte subsets was affected in Covid-19 182 patients. Monocyte subsets were analyzed for CD14, CD16 and HLA-DR expression by flow 183 cytometry in 76 Covid-19 patients and compared to healthy blood donors (Figure 4A). In the 184 latter, classical monocytes were the best represented monocyte subset (9.17% of total 185 PBMCs), while intermediate and non-classical monocytes accounted for 0.42% and 0.60%, 186 respectively. In Covid-19 patients, the percentages of classical (2.03%), intermediate (0.23%) 187 and non-classical monocytes (0.22%) were significantly lower than in healthy controls 188 (Figure 4A). Hence, the monocytopenia previously reported in patients infected with SARS-189 CoV-2 (25) affected all three monocyte subsets. We wondered if circulating monocytes 190 displayed changes in the expression level of activation-associated membrane markers. Hence, 191 we measured the expression of HLA-DR, a canonical marker of monocyte activation, and 192 CD163, an immunoregulatory marker. As shown in **figure 4B**, all three monocyte subsets 193 expressed HLA-DR and CD163. In Covid-19 patients, the expression level of HLA-DR was 194 significantly decreased in intermediate and non-classical monocytes, whereas it remained 195 similar to controls in classical monocytes (Figure 4B). In contrast, the expression of CD163 196 was significantly increased in classical and non-classical monocytes (Figure 4B). The 197 opposite effect of Covid-19 on HLA-DR and CD163 expression suggests that their activation 198 status was shifted to an immunoregulatory program. This phenotypic profile of patient 199 monocytes was partly recapitulated by incubating control monocytes with SARS-CoV-2. 200 SARS-CoV-2 increased HLA-DR expression in a dose dependent manner after 24 hours and 201 decreased it after 48 hours. The inverted pattern was observed with CD163 (Figure 4C). 202 Finally, we wondered if the decrease in monocyte subsets and altered expression of HLA-DR 203 and CD163 reflected the severity of Covid-19. There were no significant differences in 204 monocyte phenotype among mild, moderate, and severe patients (Figure 5). Hence variation 205 of monocyte HLA-DR and CD163 expression in Covid-19 patients was induced by SARS-206 CoV-2 infection, but was not related to subsequent disease severity.

207 **Discussion**

208 We showed that SARS-CoV-2 efficiently infects human monocytes and macrophages. 209 This is reminiscent of previous reports about SARS-CoV-1 that infects human macrophages 210 but does not replicate within (26). In addition, macrophages infected by SARS-CoV-1 were 211 detected in lungs of SARS patients (5). Recently, post-mortem examination of lymph nodes 212 and spleen revealed the presence of SARS-CoV-2 nucleocapsid protein in macrophages that 213 express CD169, a maker of macrophages from the splenic marginal zone (8). Using an 214 unsupervised computational pipeline that can detect viral RNA in any scRNA-seq data set, an 215 enrichment of SARS-CoV-2 reads in macrophages expressing secreted phosphoprotein 1 was 216 observed (27). Although monocytes and macrophages express the molecular machinery to 217 recognize and internalize SARS-CoV-2 such as ACE2, TMPRSS2 and ADAM17 (24), the 218 ability of the virus to replicate within these cells is not fully understood. Our results favor the 219 hypothesis of an abortive infection similar to SARS-CoV-1 (28) but clearly distinct from 220 MERS-CoV replication in macrophages (29).

221 The infection of monocytes and macrophages is associated with the production of 222 inflammatory cytokines that contribute to the CRS described in patients and involved in 223 disease pathogenesis. Monocytes and macrophages exhibit a common secretory profile 224 associating the release of IL-6, IL-10 and TGF- β and the absence of IFN- β . The impaired IFN 225 production is consistent with the reported inhibition of type I IFNs by SARS-CoV-1 and the 226 lack of interferon regulatory factor 3 activation in macrophages and myeloid dendritic cells 227 (5). In addition to preventing IFN- α/β responses, SARS-CoV downregulated IFN-related 228 genes in THP-1 cell lines (30). At least three SARS-CoV proteins, namely N protein, OrfB3 229 and Orf6, are known to antagonize the IFN- β response (31). While the release of IL-6 is 230 consistent with previous reports on the ability of SARS-CoV-1 to stimulate IL-6 secretion in 231 human MDM, the lack of significant changes in TNF release was not expected (26). It has 232 been shown in an *in-situ* study of *post-mortem* samples that SARS-CoV-2 induces IL-6 more 233 efficiently than TNF (8). In our hands, both monocytes and macrophages released IL-10 and 234 TGF- β , suggesting that anti-inflammatory cytokines are also involved in cell responses to 235 infection. The release of TGF- β by monocytes and macrophages may be associated with 236 tissue repair and generation of fibrosis that complicates Covid-19 evolution (32). Taken 237 together, our results suggest that the early response of monocytes and macrophages is 238 inflammatory whereas the delayed response promotes tissue repair. This model is in line with 239 the immune response unfolding in Covid-19 patients, in whom myeloid cells interact with innate and adaptive immune partners able to redirect immune responses towards aninflammatory status.

242 We found that SARS-CoV-2 differently affected the transcriptional programs of 243 monocytes and macrophages. In monocytes, SARS-CoV-2 elicited a transient program 244 dominated by the upregulation of IFN α gene, while macrophages exhibited a more diversified 245 transcriptional program associating inflammatory and anti-inflammatory genes, which shifted 246 to an anti-inflammatory program of M2 type. Hence, SARS-CoV-2 affected macrophage 247 polarization according to the kinetics of infection. Previous reports on SARS-CoV-1 infection 248 showed a direct effect of virus on macrophage activation. In an African green monkey model, 249 SARS-CoV-1 activated pulmonary macrophages by polarizing them toward a M1 profile 250 associated with decreased viral load but persistence of inflammation (33). In a murine model 251 of SARS-CoV-1 infection, alveolar macrophages were repolarized to limit T cell activation 252 (34). Another study revealed that SARS-CoV-1 induced non protective M2 polarization in 253 lung macrophages from infected mice(35). Whether macrophage polarization affected their 254 capacity to control SARS-CoV-2 replication was not addressed. Using polarized MDM and 255 differentiated THP-1 cells, we found that non polarized and M1 type polarized macrophages 256 were permissive to SARS-CoV-2. This may explain why obesity and diabetes, conditions 257 associated with M1 macrophage polarization, are critical comorbidities in Covid-19 (36). In 258 our hands, M2 type macrophages tended to be less permissive to SARS-CoV-2. As estrogens 259 favor M2 polarization (37), this may explain why women are less affected than men by 260 Covid-19. In addition, patients with allergic asthma seem to be less susceptible to the virus 261 (38). Our results suggest that, instead of inducing a clear polarization, SARS-CoV-2 262 exacerbates macrophage responses whatever the type of polarization.

263 The myeloid compartment was analyzed through monocyte frequencies and the 264 expression of membrane markers. Previous reports established that monocytopenia was 265 detected in Covid-19 patients in association with lymphopenia. We showed that this decrease 266 in circulating monocytes affects all monocyte subsets. There is a lack of consensus about the 267 variations of monocyte count in Covid-19, probably because of the diversity of measurement 268 tools and the heterogeneity of patients in terms of evolution. A.J. Wilk *et al* reported depletion 269 of CD16⁺ monocytes including intermediate and non-classical monocytes in a single-cell 270 RNA sequencing study of Covid-19 PBMCs (39). A Cytof study of CD45⁺ mononuclear cells 271 revealed an initial increase in cell count from mild to severe followed by a decline in more 272 severe patients (40). Expansion of IL-6 producing CD14⁺CD16⁺ monocytes was reported in 273 Covid-19 patients hospitalized in intensive care units (ICU) as compared with patients not274 requiring ICU care (32).

275 Besides monocyte depletion in patients, remaining monocytes were characterized by a 276 down-modulation of HLA-DR and upregulation of CD163. HLA-DR down-modulation is in 277 agreement with previous studies. A. Gatti et al reported downregulation of monocyte HLA-278 DR in patients with severe SARS-CoV-2 (41). A sc-RNA seq study revealed that genes 279 encoding class II HLA molecules were downmodulated in Covid-19 patients(39). P. Bost 280 reported a disease-severity-associated signature in MDM in which MHC II and type I IFN 281 genes were downmodulated (27). Another study showed that CD14⁺ monocytes maintained 282 the expression of HLA-DR in mild/moderate patients, with down-modulation occurring only 283 in severe forms (42). Previously unreported CD163 upregulation in Covid-19 patients 284 suggests a monocyte polarization toward a M2-type profile. Immunohistochemical staining of 285 SARS pneumonia demonstrated CD163⁺ M2 macrophages in situ (43). M2 polarization is the 286 consequence of the release of immunoregulatory cytokines, but also of the interaction with the 287 virus. Indeed, we showed a trend in monocytes infected with SARS-CoV-2 with an increase 288 in CD163 expression paralleling low HLA-DR expression. It is known that IL-6 antagonizes 289 HLA-DR expression and the addition of the specific inhibitor of IL-6 pathway, tocilizumab, 290 partially restores HLA-DR expression of CD14⁺ monocytes from Covid-19 patients (42). A 291 synergism between SARS-CoV-2 and IL-6 is likely necessary to down-modulate the 292 expression of HLA-DR and to disarm microbicidal competence of monocytes and 293 macrophages.

294 Here, we showed that SARS-CoV-2 infects monocytes and macrophages without 295 cytopathic effect and induces a more sustained activation program in macrophages. Monocyte 296 and macrophage response to SARS-CoV-2 is more complex than expected from the 297 observation of CRS, to which they poorly contribute. The investigation of circulating 298 monocytes suggested that massive migration to tissues had occurred and remaining blood 299 monocytes exhibit a repairing profile. This observation may help understand the risk of post-300 Covid-19 complication including fibrosis. Indeed, a subset of macrophages with a pro-fibrotic 301 program has been described in patients with Covid-19 (32). The lack of correlation between 302 monocyte count and monocyte functional polarization with severity stages suggest that 303 monocytes are markers of SARS-CoV-2 infection. It is likely that other membrane markers of 304 myeloid cells are modulated according to disease progression and reflect more accurately the 305 inflammatory context associated with the severity. Taken together, our study showed that bioRxiv preprint doi: https://doi.org/10.1101/2020.09.17.300996. this version posted September 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

- 306 monocytes and macrophages are targets of SARS-CoV-2, and their manipulation may open
- 307 the way for therapeutic perspectives.

308 Methods

309 Patients and ethical statement

310 Seventy-six consecutive patients with SARS-CoV-2 infection confirmed through reverse 311 transcriptase-polymerase chain reaction (RT-PCR, Life Technologies, Carlsbad, CA, USA) 312 from March 16 through March 27, 2020 at the University Hospitals of Marseille, France, were 313 included. Not later than 48 hours post-diagnosis, patients underwent clinical laboratory tests 314 and blood was drawn through venipuncture into EDTA anticoagulated tubes. 315 Epidemiological, demographic, clinical, laboratory and outcome data were obtained from a 316 retrospective, non-interventional review of the medical charts and laboratory results. 317 Demographic characteristics of the study population are presented in table 1. This study was 318 performed on excess EDTA-anticoagulated total blood samples. According to French law, the 319 patients had received information that their excess samples and clinical data might be used for 320 research purposes, and retained the right to oppose (15,16).

321

322 Cell isolation

323 Peripheral blood mononuclear cells (PBMCs) were isolated from the blood of Covid-19 324 patients and from buffy coats from healthy blood donors (Convention $N^{\circ}7828$, "Etablissement 325 Français du Sang", Marseille, France) by density gradient centrifugation using Ficoll 326 (Eurobio, Les Ulis, France) as previously described (17). Monocytes were purified by CD14 327 selection using MACS magnetic beads (Miltenyi Biotec, Bergisch Glabach, Germany) and 328 cultured in Roswell Park Memorial Institute medium-1640 (RPMI, Life Technologies, 329 Carlsbad, CA, USA) containing 10% inactivated human AB-serum, 2 mM glutamine (Sigma 330 Aldrich, Saint-Quentin-Fallavier, France), 100 U/mL penicillin and 50 µg/mL streptomycin 331 (Life Technologies). After 3 days, the medium was replaced by RPMI-1640 containing 10% 332 fetal bovine serum (FBS, Life Technologies) and 2 mM glutamine, and cells were 333 differentiated into macrophages for 4 additional days. For some experiments, THP-1 334 macrophages were used and cultured in RPMI-1640 containing 10% FBS, 2mM glutamine 335 and 100 U/mL penicillin and 50 µg/mL streptomycin and differentiated into macrophages 336 after treatment with 50 ng/ml phorbol-12-myristate 13-acetate (PMA, Sigma Aldrich) for 48 337 hours (18,19).

338

339 Virus production and cell infection

SARS-CoV-2 strain IHU-MI3 was obtained after Vero E6 cells (American type culture
 collection ATCC® CRL-1586TM) infection in Minimum Essential Media (MEM) (Life

- 342 Technologies) supplemented with 4% FBS as previously described (20).
- 343 Cells were infected with 50 µl virus suspension (0.25, 0.5 or 0.1 multiplicity of infection
- (MOI)) for 24 or 48 hours at 37° C in the presence of 5% CO₂ and 95% air in a humidified
- 345 incubator.
- 346

347 Immunofluorescence

348 After a 24 or 48-hour infection, cells were incubated in blocking buffer (Phosphate buffer

saline (PBS) supplemented with 5% FBS and 0.5% Triton X-100) for 30 minutes and washed

350 before incubation with an anti-SARS-CoV-2 spike protein antibody (Life Technologies).

351 Nuclei and F-actin were stained using DAPI and Phalloidin (Life Technologies) respectively.

- 352 Pictures were obtained using an LSM800 Airyscan confocal microscope (Zeiss) and a 63X oil
- 353 objective.
- 354

355 Viral RNA extraction and q-RTPCR

Viral RNA was extracted from infected cells using NucleoSpin® Viral RNA Isolation kit (Macherey-Nagel, Hoerdt, France) following the manufacturer's recommendations. Virus detection was performed using One-Step RT-PCR SuperScript[™] III Platinum[™] Kit (Life Technologies). Thermal cycling was achieved at 55°C for 10 minutes for reverse transcription, pursued by 95°C for 3 minutes and then 45 cycles at 95°C for 15 seconds and 58°C for 30 seconds using a LightCycler 480 Real-Time PCR system (Roche, Rotkreuz, Switzerland). The primers and the probes were designed against the E gene (20).

363

364 **RNA isolation and q-RTPCR**

Total RNA was extracted from monocytes or macrophages $(2.10^6 \text{ cells/well})$ using the 365 366 RNeasy Mini Kit (Qiagen, Courtaboeuf, France) and DNase I treatment to eliminate DNA 367 contaminants (21). The quality and quantity were evaluated using a spectrophotometer 368 (Nanodrop Technologies, Wilmington, USA). Reverse transcription of isolated RNA was 369 performed using a Moloney murine leukemia virus-reverse transcriptase kit (Life 370 Technologies) and oligo(dT) primers. q-PCR was performed using the Smart SYBRGreen fast 371 Master kit (Roche Diagnostics, Meylan, France) and a CFX Touch RTPCR Detection System 372 (Bio-Rad, Marnes-la-Coquette, France) using specific primers (Table 2). The results were 373 normalized using the housekeeping endogenous control *actb* gene encoding β -actin and are

374 expressed as relative expression of investigated genes using the formula $2^{-\Delta Ct}$ where $\Delta Ct =$

375 Ct_{Target} - Ct_{Actin} as previously described (22). The threshold cycle (Ct) was defined as the

- number of cycles required to detect the fluorescent signal.
- 377

378 Immunoassays

- 379 Cell supernatants were collected and the release of IL-10, tumor necrosis factor (TNF)-α, IL-
- 380 1β, interferon (IFN)-β, transforming growth factor (TGF)-β1 (R&D Systems, Bio-Techne,
- 381 Novel Châtillon sur Seiche, France) and IL-6 (Clinisciences, Nanterre, France) was quantified
- using specific immunoassay kits. The sensitivity of the assays was (pg/ml) 15.4 for IL-6, 3.9
- for IL-10, 5.5 for TNF- α , 0.125 for IL-1 β , 50 for IFN- β and 4.61 for TGF- β 1.
- 384

385 Flow cytometry

386 PBMCs from healthy donors or Covid-19 patients were resuspended in PBS (Life 387 Technologies) containing 5% FBS and 2mM EDTA (Sigma-Aldrich) for 20 minutes before 388 staining using the following fluorochrome-conjugated antibodies (mouse IgG1): CD3 389 (UCHT1), CD20 (B9E9), CD14 (RMO52), CD16 (3G8) purchased from Beckman Coulter, 390 Paris, France; HLA-DR (G46-6) and CD163 (GHI/61) from BD Biosciences, Le Pont de 391 Claix, France, and appropriate isotype controls. A minimum of 50,000 events were acquired 392 for each sample using a BD Canto II instrument (BD Biosciences) and data were analyzed 393 with FlowJo software (Tree Star, Ashland, OR).

394

395 Statistical analysis

396 Statistical analysis was performed with GraphPad Prism (7.0, La Jolla, CA), using the two-397 way ANOVA test for viral quantification (Ct values) and transcriptional analysis, 398 nonparametric Kruskall-Wallis test for group comparison, nonparametric Mann-Whitney U399 test for cytokine levels, and nonparametric t-test for flow cytometry results with monocyte 400 populations and surface marker expression. Turkey's and Sidak's tests were used for post-hoc 401 comparisons. qRT-PCR data for monocytes and macrophages, including principal component 402 analysis (PCA) and hierarchical clustering of gene expression, were analyzed using the 403 ClustVis webtool (23). Differences were considered statistically significant at P < 0.05.

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.17.300996. this version posted September 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

404 **Authorship contributions**

- 405 A.B, L.G, S.M, A.B.B, M.M and J.V performed the experiments and analyzed the data. S.M,
- 406 B.D, D.R, B.L.S, P.H, J.V, D.O and J.L.M supervised the work. S.M, J.V and J.L.M wrote the

407 paper. All the authors read and approved the final manuscript.

- 408 Acknowledgments
- 409

410 Dr. Corinne Brunet, Pr. Françoise Dignat-George and Dr. Romaric Lacroix, for assistance 411 with immunophenotyping and sample tracking. Asma Boumaza was supported by the 412 "Fondation Méditerranée Infection". Soraya Mezouar was first supported by the "Fondation 413 pour la Recherche Médicale" postdoctoral fellowship (reference: SPF20151234951) and then 414 by the "Fondation Méditerranée Infection". This work was supported by the French 415 Government under the "Investissements d'avenir" (investments for the future) program 416 managed by the "Agence Nationale de la Recherche" (reference: 10-IAHU-03). The team 417 "Immunity and Cancer" was labeled "Equipe FRM DEQ 201 40329534" (for DO). This work 418 was supported by the IMMUO-COVID project managed by the "Agence Nationale de la 419 Recherche" Flash Covid (reference: IMMUNO-COVID).

420

421 Disclosure of conflicts of interest

J.V reports speaker and consultancy fees from Thermo Fisher Scientific, Meda Pharma
(Mylan), Beckman Coulter, Sanofi, outside the submitted work. D.O is cofounder and
shareholder of Imcheck Therapeutics Emergence Therapeutics and Alderaan. The other
authors declare that they have no competing interests.

426 **References**

- 427 1. https://gisanddata.maps.arcgis.com/apps/opsdashboard /index.html#/bda 7594740
 428 fd40299423467b48e9ecf6.
- Zhou F, Fan G, Liu Z, Cao B. SARS-CoV-2 shedding and infectivity Authors' reply.
 The Lancet (2020) **395**:1340. doi:10.1016/S0140-6736(20)30869-2
- 431 3. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. *Science* (2020)
 432 368:473-474. doi:10.1126/science.abb8925
- 4. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, et al.
 Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* (2020) 8:420–422. doi:10.1016/S2213-2600(20)30076-X
- 436 5. Dandekar AA, Perlman S. Immunopathogenesis of coronavirus infections: implications
 437 for SARS. *Nat Rev Immunol* (2005) 5:917–927. doi:10.1038/nri1732
- 438 6. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and 439 consequences of cytokine storm and immunopathology. *Semin Immunopathol* (2017)
 440 **39**:529–539. doi:10.1007/s00281-017-0629-x
- 441 7. Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, Wei Q, Yu P, Xu Y, Qi F, et al. The
 442 pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. *Nature* (2020)
 443 doi:10.1038/s41586-020-2312-y
- ken yongwen, Feng Z, Diao B, Wang R, Wang G, Wang C, Tan Y, Liu L, Wang C, Liu
 Y, et al. The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
 Directly Decimates Human Spleens and Lymph Nodes. Infectious Diseases (except HIV/AIDS) (2020). doi:10.1101/2020.03.27.20045427
- Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, Chen L, Li J, Wang X, Wang F, et al. The
 landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell
 RNA sequencing. Allergy and Immunology (2020). doi:10.1101/2020.02.23.20026690
- 10. Narasimhan PB, Marcovecchio P, Hamers AAJ, Hedrick CC. Nonclassical Monocytes in
 Health and Disease. *Annu Rev Immunol* (2019) **37**:439–456. doi:10.1146/annurevimmunol-042617-053119
- Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. *Blood* (1989) 74:2527–2534.
- Patel AA, Zhang Y, Fullerton JN, Boelen L, Rongvaux A, Maini AA, Bigley V, Flavell
 RA, Gilroy DW, Asquith B, et al. The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. *J Exp Med* (2017) **214**:1913–1923. doi:10.1084/jem.20170355
- 460 13. Guilliams M, Mildner A, Yona S. Developmental and Functional Heterogeneity of
 461 Monocytes. *Immunity* (2018) 49:595–613. doi:10.1016/j.immuni.2018.10.005

462 14. Bassler K, Schulte-Schrepping J, Warnat-Herresthal S, Aschenbrenner AC, Schultze JL.
463 The myeloid cell compartment-cell by cell. *Annu Rev Immunol* (2019) **37**:269–293.
464 doi:10.1146/annurev-immunol-042718-041728

- LOI n° 2012-300 du 5 mars 2012 relative aux recherches impliquant la personne humaine. (2012).
- 467 16. Décret n° 2016-1537 du 16 novembre 2016 relatif aux recherches impliquant la personne
 468 humaine. (2016).
- 469 17. Mezouar S, Omar Osman I, Melenotte C, Slimani C, Chartier C, Raoult D, Mege J-L,
 470 Devaux CA. High concentrations of serum soluble E-cadherin in patients with Q fever.
 471 *Front Cell Infect Microbiol* (2019) **9**:219. doi:10.3389/fcimb.2019.00219
- 472 18. Chanput W, Mes JJ, Savelkoul HFJ, Wichers HJ. Characterization of polarized THP-1
 473 macrophages and polarizing ability of LPS and food compounds. *Food Funct* (2013)
 474 4:266–276. doi:10.1039/C2FO30156C
- 19. Daigneault M, Preston JA, Marriott HM, Whyte MKB, Dockrell DH. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. *PloS One* (2010) **5**:e8668.
 478 doi:10.1371/journal.pone.0008668
- Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, Wurtz N, Rolain
 J-M, Colson P, La Scola B, et al. In vitro testing of combined hydroxychloroquine and
 azithromycin on SARS-CoV-2 shows synergistic effect. *Microb Pathog* (2020)
 145:104228. doi:10.1016/j.micpath.2020.104228
- 483 21. Mezouar S, Vitte J, Gorvel L, Ben Amara A, Desnues B, Mege J-L. Mast cell cytonemes
 484 as a defense mechanism against *Coxiella burnetii*. *mBio* (2019) 10:e02669-18.
 485 doi:10.1128/mBio.02669-18
- 486
 487
 487
 487
 488
 488
 488
 488
 488
 489
 489
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
- 490 23. Metsalu T, Vilo J. ClustVis: a web tool for visualizing clustering of multivariate data
 491 using Principal Component Analysis and heatmap. *Nucleic Acids Res* (2015) 43:W566492 570. doi:10.1093/nar/gkv468
- 493 24. Abassi Z, Knaney Y, Karram T, Heyman SN. The lung macrophage in SARS-CoV-2
 494 infection: A friend or a foe? *Front Immunol* (2020) 11:1312.
 495 doi:10.3389/fimmu.2020.01312
- 496 25. Fan BE, Chong VCL, Chan SSW, Lim GH, Lim KGE, Tan GB, Mucheli SS, Kuperan P,
 497 Ong KH. Hematologic parameters in patients with COVID 19 infection. *Am J Hematol*498 (2020) 95: doi:10.1002/ajh.25774
- Tseng C-TK, Perrone LA, Zhu H, Makino S, Peters CJ. Severe acute respiratory
 syndrome and the innate immune responses: modulation of effector cell function without

501productive infection. J Immunol Baltim Md 1950 (2005)174:7977–7985.502doi:10.4049/jimmunol.174.12.7977

- 503 27. Bost P, Giladi A, Liu Y, Bendjelal Y, Xu G, David E, Blecher-Gonen R, Cohen M,
 504 Medaglia C, Li H, et al. Host-Viral Infection Maps Reveal Signatures of Severe COVID505 19 Patients. *Cell* (2020) 181:1475-1488.e12. doi:10.1016/j.cell.2020.05.006
- 506 28. Yilla M, Harcourt BH, Hickman CJ, McGrew M, Tamin A, Goldsmith CS, Bellini WJ, 507 SARS-coronavirus replication peripheral Anderson LJ. in human 508 monocytes/macrophages. Virus Res (2005)**107**:93–101. 509 doi:10.1016/j.virusres.2004.09.004
- 29. Zhou J, Chu H, Li C, Wong BH-Y, Cheng Z-S, Poon VK-M, Sun T, Lau CC-Y, Wong
 KK-Y, Chan JY-W, et al. Active replication of Middle East respiratory syndrome
 coronavirus and aberrant induction of inflammatory cytokines and chemokines in human
 macrophages: implications for pathogenesis. *J Infect Dis* (2014) 209:1331–1342.
 doi:10.1093/infdis/jit504
- 515 30. Hu W, Yen Y-T, Singh S, Kao C-L, Wu-Hsieh BA. SARS-CoV Regulates Immune
 516 Function-Related Gene Expression in Human Monocytic Cells. *Viral Immunol* (2012)
 517 25:277–288. doi:10.1089/vim.2011.0099
- 518 31. Hu Y, Li W, Gao T, Cui Y, Jin Y, Li P, Ma Q, Liu X, Cao C. The Severe Acute
 519 Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production
 520 by Interfering with TRIM25-Mediated RIG-I Ubiquitination. *J Virol* (2017) 91:e02143521 16, e02143-16. doi:10.1128/JVI.02143-16
- Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role
 for monocytes and macrophages. *Nat Rev Immunol* (2020) 20:355–362.
 doi:10.1038/s41577-020-0331-4
- S1. Clay C, Donart N, Fomukong N, Knight JB, Lei W, Price L, Hahn F, Van Westrienen J, Harrod KS. Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge. *J Virol* (2012)
 S6:4234–4244. doi:10.1128/JVI.06791-11
- 34. Zhao J, Zhao J, Van Rooijen N, Perlman S. Evasion by Stealth: Inefficient Immune
 Activation Underlies Poor T Cell Response and Severe Disease in SARS-CoV-Infected
 Mice. *PLoS Pathog* (2009) 5:e1000636. doi:10.1371/journal.ppat.1000636
- 532 35. Page C, Goicochea L, Matthews K, Zhang Y, Klover P, Holtzman MJ, Hennighausen L,
 533 Frieman M. Induction of alternatively activated macrophages enhances pathogenesis
 534 during severe acute respiratory syndrome coronavirus infection. *J Virol* (2012)
 535 86:13334–13349. doi:10.1128/JVI.01689-12
- 536 36. Brufsky A. Hyperglycemia, hydroxychloroquine, and the COVID 19 pandemic. *J Med* 537 *Virol* (2020) 92:770–775. doi:10.1002/jmv.25887
- 538 37. Villa A, Rizzi N, Vegeto E, Ciana P, Maggi A. Estrogen accelerates the resolution of
 539 inflammation in macrophagic cells. *Sci Rep* (2015) 5:15224. doi:10.1038/srep15224

- 38. Morais-Almeida M, Aguiar R, Martin B, Ansotegui IJ, Ebisawa M, Arruda LK,
 Caminati M, Canonica GW, Carr T, Chupp G, et al. COVID-19, asthma, and biological
 therapies: What we need to know. *World Allergy Organ J* (2020) 13:100126.
 doi:10.1016/j.waojou.2020.100126
- Wilk AJ, Rustagi A, Zhao NQ, Roque J, Martinez-Colon GJ, McKechnie JL, Ivison GT,
 Ranganath T, Vergara R, Hollis T, et al. A single-cell atlas of the peripheral immune
 response to severe COVID-19. Infectious Diseases (except HIV/AIDS) (2020).
 doi:10.1101/2020.04.17.20069930
- 40. Wang W, Su B, Pang L, Qiao L, Feng Y, Ouyang Y, Guo X, Shi H, Wei F, Su X, et al.
 High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients. *Cell Mol Immunol* (2020) 17:650– 652. doi:10.1038/s41423-020-0447-2
- 41. Gatti A, Radrizzani D, Viganò P, Mazzone A, Brando B. Decrease of non □ classical and
 intermediate monocyte subsets in severe acute SARS □ CoV □ 2 infection. *Cytometry A*(2020)cyto.a.24188. doi:10.1002/cyto.a.24188
- 42. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A,
 Antonakos N, Damoraki G, Gkavogianni T, Adami M-E, Katsaounou P, et al. Complex
 Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. *Cell Host Microbe* (2020) 27:992-1000.e3. doi:10.1016/j.chom.2020.04.009
- 43. Zeng Z, Xu L, Xie X, Yan H, Xie B, Xu W, Liu X, Kang G, Jiang W, Yuan J.
 Pulmonary Pathology of Early Phase COVID 19 Pneumonia in a Patient with a Benign Lung Lesion. *Histopathology* (2020)his.14138. doi:10.1111/his.14138

562

- 563 Tables
- 564 Table 1. Clinical and demographic data of the study population. Seventy-six consecutive
- 565 Covid-19 patients and 41 healthy controls were analyzed. Demographic data were available
- 566 for 40 healthy controls. Nonparametric Kruskall-Wallis test was used for group comparison.
- 567 HC, healthy control; F, female, M, male.

Clinical	Covid-19 patients			Healthy	P value	
status	Severe	Moderate	Mild	All	controls	r value
Sample	14	21	41	76	40	
size (%)	(18)	(28)	(54)	(100)		
Median age (range)	73 (45-95)	56 (29-82)	53 (18-85)	58 (18-95)	40 (18-68)	<0.0001 (with HC) 0.006 (COVID groups only)
Gender (M/F)	12/2	8/13	19/22	39/37	22/18	0.03 (with HC) 0.02 (COVID groups only)
Deceased	8	0	0	0	0	<0.0001 (COVID groups only)

568

569 **Table 2. List of primers used for q-RTPCR.**

Gene	Forward primer (5'-3')	Reverse primer (5'-3')
actb	GGAAATCGTGCGTGACATTA	AGGAGGAAGGCTGGAAGAG
TNF	AGGAGAAGAGGCTGAGGAACAAG	GAGGGAGAGAAGCAACTACAGACC
CXCL	GGAAATCGTGCGTGACATTA	AGGAAGGAAGGCTGGAAGAG
10		
IL1B	CAGCACCTCTCAAGCAGAAAAC	GTTGGGCATTGGTGTAGACAAC
IL6	CCAGGAGAAGATTCCAAAGATG	GGAAGGTTCAGGTTGTTTTCTG
IL10	GGGGGTTGAGGTATCAGAGGTAA	GCTCCAAGAGAAAGGCATCTACA
TGFB	GACATCAAAAGATAACCACTC	TCTATGACAAGTTCAAGCAGA
IFNA	ACAACCTCCCAGGCACAAGGGCTGT	TGATGGCAACCAGTTCCAGAAGGCTC
	ATTT	AAG
IFNB	GTTCCTTAGGATTTCCACTCTGACTA	GAACTTTGACATCCCTGAGGAGATTA
	TGGTCC	AGCAGC
IFNG	GTTTTGGGTTCTCTTGGCTGTTA	ACACTCTTTTGGATGCTCTGGTC
IL8	CTGGCCGTGGCTCTCTTG	TTCCACGTCAAAACGGTTCC
CD163	CGGTCTCTGTGATTTGTAACCAG	TACTATGCTTTCCCCATCCATC

570

571

572 Figure legends

573 Figure 1. SARS-CoV-2 infects monocytes and macrophages and stimulates cytokine 574 release. Vero E6 cells, monocytes and monocyte-derived macrophages were infected with 575 SARS-CoV-2 IHU-MI3 strain (0.1 MOI) for 24 or 48 hours. (A) SARS-CoV-2 quantification 576 was evaluated by RT-PCR, expressed as Ct values and observed in red in infected cells, with 577 the nucleus in blue and F-actin in green (n = 3). Pictures were acquired using a confocal 578 microscope (63x). ****P < 0.0001 using two-way ANOVA and Turkey's test for post-hoc 579 comparisons. (**B**, **C**) Pro- (IFN- β , IL-6, TNF- α , IL-1 β) and anti-inflammatory (TGF- β , IL-10) 580 cytokines release was evaluated for SARS-CoV-2-infected monocytes and macrophages at 581 (B) 24 and (C) 48 hours (n=6). Values represent mean \pm standard error of the mean. *P < 582 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 using Mann-Whitney U test.

583

584 Figure 2. SARS-CoV-2 elicits a specific transcriptional program in macrophages. 585 Monocytes and macrophages were stimulated with SARS-CoV-2 IHU-MI3 strain (0.1 MOI) 586 for 24 or 48 hours (n = 6). The expression of genes involved in the inflammatory response 587 (IFNA, IFNB, IFNG, TNF, IL1B, IL6, IL8, CXCL10) or immunoregulation (IL10, TGFB1, 588 CD163) was investigated by qRT-PCR after normalization with housekeeping actin gene as 589 endogenous control. (A) Data are illustrated as principal component analysis obtained using 590 ClustVis webtool for uninfected and SARS-CoV-2 infected cells in red and blue respectively, 591 with round points for 24 hours and square points for 48 hours of stimulation. (B) Relative 592 quantity of investigated genes at 24 hours of stimulation was evaluated for monocytes (left 593 panel) and macrophages (right panel). Values represent mean \pm standard error of the mean. *P 594 < 0.05, **P < 0.01 and ***P < 0.001 using two-way ANOVA and Sidak's test for post-hoc 595 comparisons.

596

597 Figure 3. Investigation of polarized macrophages in the SARS-CoV-2 response. 598 Macrophages and PMA-differentiated THP-1 cells were polarized by treatment with IFN-599 γ (20 ng/ml) and lipopolysaccharide (100 ng/ml) (M1), IL-4 (20 ng/ml) (M2) or without 600 agonist (M0). Polarized macrophages were stimulated for (A) 24 or (B) 48 hours with IHU-601 MI3 SARS-CoV-2 strain and IL-6, IL-10, TNF- α and TGF- β release were evaluated in the culture supernatants by ELISA (n = 3). *P < 0.05, **P < 0.01 and ***P < 0.001 using Mann-602 603 Whitney U test. (C) Virus quantification was assessed by the evaluation of the Ct values for 604 polarized SARS-CoV-2-infected macrophages (n = 3) and PMA-differentiated THP-1 cells (n 605 = 6) at 24 hours post-infection. Values represent mean \pm standard error of the mean. *P < 0.05

- 606 using two-way ANOVA and Turkey's test for post-hoc comparisons.
- 607

608 Figure 4. Monocyte subsets are altered in SARS-CoV-2-infected patients. PBMCs from 609 healthy donors and Covid-19 patients were isolated and monocyte sub-populations were 610 investigated by flow cytometry (A) Representative flow cytometry plot showing the gating 611 strategy to investigate non-classical, classical and intermediate HLA-DR⁺ monocytes from 612 Covid-19 patients and healthy donors as control. (B) Mean fluorescence intensity (MFI) of HLA-DR and CD163 expression was investigated for CD14⁺, CD14⁺/CD16⁺ and CD16⁺ 613 614 monocyte populations from healthy and Covid-19 patients. (C) Monocytes from healthy 615 donors were stimulated with SARS-CoV-2 IHU-MI3 strain (0.25 or 0.5 MOI). The expression 616 of HLA-DR and CD163 was observed at 24 and 48 hours of infection. **P < 0.01, ***P < 0.010.001 and *****P* < 0.0001 using t-test. 617

618

619 **Figure 5.**


620 Peripheral blood mononuclear cells from Covid-19 patients were isolated and monocyte sub-621 populations were investigated by flow cytometry. (A) Non-classical, classical and


622 intermediate HLA-DR⁺ monocytes were evaluated from moderate, mild and severe Covid-19


- 623 clinical population. (B) Mean fluorescence intensity (MFI) of HLA-DR and CD163
- 624 expression was investigated for CD14⁺, CD14⁺/CD16⁺ and CD16⁺ monocyte populations
- from moderate, mild and severe Covid-19 patients using t-test.


A.


Figure 1 ^{48h}












A.

B.


C.





MOI 0.25 MOI 0.50 None [

Figure 5



B.

